1 Min Read
March 31 (Reuters) - Miragen Therapeutics Inc:
* Miragen Therapeutics receives orphan-drug designation for MRG-106 for the treatment of mycosis fungoides Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.